Effect of database profile variation on drug safety assessment: an analysis of spontaneous adverse event reports of Japanese cases.
BACKGROUND: The use of a statistical approach to analyze cumulative adverse event (AE) reports has been encouraged by regulatory authorities. However, data variations affect statistical analyses (eg, signal detection). Further, differences in regulations, social issues, and health care systems can cause variations in AE data. The present study examined similarities and differences between two publicly available databases, ie, the Japanese Adverse Drug Event Report (JADER) database and the US Food and Drug Administration Adverse Event Reporting System (FAERS), and how they affect signal detection.
METHODS: Two AE data sources from 2010 were examined, ie, JADER cases (JP) and Japanese cases extracted from the FAERS (FAERS-JP). Three methods for signals of disproportionate reporting, ie, the reporting odds ratio, Bayesian confidence propagation neural network, and Gamma Poisson Shrinker (GPS), were used on drug-event combinations for three substances frequently recorded in both systems.
RESULTS: The two databases showed similar elements of AE reports, but no option was provided for a shareable case identifier. The average number of AEs per case was 1.6+/-1.3 (maximum 37) in the JP and 3.3+/-3.5 (maximum 62) in the FAERS-JP. Between 5% and 57% of all AEs were signaled by three quantitative methods for etanercept, infliximab, and paroxetine. Signals identified by GPS for the JP and FAERS-JP, as referenced by Japanese labeling, showed higher positive sensitivity than was expected.
CONCLUSION: The FAERS-JP was different from the JADER. Signals derived from both datasets identified different results, but shared certain signals. Discrepancies in type of AEs, drugs reported, and average number of AEs per case were potential contributing factors. This study will help those concerned with pharmacovigilance better understand the use and pitfalls of using spontaneous AE data.
|ジャーナル名||Drug design, development and therapy|
|投稿者||Nomura, Kaori; Takahashi, Kunihiko; Hinomura, Yasushi; Kawaguchi, Genta; Matsushita, Yasuyuki; Marui, Hiroko; Anzai, Tatsuhiko; Hashiguchi, Masayuki; Mochizuki, Mayumi|
|組織名||Division of Molecular Epidemiology, Jikei University School of Medicine, Tokyo,;Japan.;Department of Biostatistics, Nagoya University Graduate School of Medicine,;Nagoya, Japan.;Japan Pharmaceutical Information Center, Tokyo, Japan.;Global Pharmacovigilance, Kissei Pharmaceutical Co Ltd, Tokyo, Japan.;Medical Affairs Department, Daiichi Sankyo Co Ltd, Keio University, Tokyo, Japan.;Drug Safety Division, Chugai Pharmaceutical Co Ltd, Keio University, Tokyo,;Data Science Center, EPS Corporation, Keio University, Tokyo, Japan.;Faculty of Pharmacy, Keio University, Tokyo, Japan.|